Table 3 Demographics and characteristics of population
Factors | Number of events(%) |
|---|---|
Gender | |
Female (%) | 67(24.72) |
Male (%) | 96(35.42) |
Not Specified (%) | 108(39.85) |
Age | |
<18(%) | 1(0. 37) |
18–44(%) | 33(12.18) |
45–64(%) | 53(19.56) |
≥65(%) | 56(20.66) |
Not Specified (%) | 128(47.23) |
Report year | |
2020(%) | 17(6.27) |
2021(%) | 26(9.59) |
2022(%) | 70(25.83) |
2023(%) | 77(28.41) |
2024Q1-Q3(%) | 81(29.89) |
Reporter | |
Consumer (%) | 15(5.54) |
Not Specified (%) | 1(0.37) |
Pharmacist (%) | 139(51.29) |
Physician (%) | 116(42.80) |
Reported countries | |
United States of America (%) | 73(26.94) |
Italy (%) | 48(17.71) |
France (%) | 41(15.13) |
Japan (%) | 26(9.59) |
Germany (%) | 24(8.86) |
Serious criteria | |
Serious reports of events | 250(92.25) |
Non-serous reports of events | 21(7.75) |
Serious outcome | |
Life-Threatening (%) | 22(8.12) |
Hospitalization - Initial or Prolonged (%) | 44(16.24) |
Disability (%) | 4(1.48) |
Death (%) | 148(54.61) |
Congenital Anomaly (%) | 0(0.00) |
Required Intervention to Prevent Permanent Impairment/Damage (%) | 1(0.37) |
Other (%) | 79(29.15) |
Adverse event occurrence time - medication date (days) | |
0–30(%) | 100(36.90) |
31–60(%) | 5(1.85) |
61–90(%) | 1(0.37) |
>90(%) | 0(0.00) |
Not Specified (%) | 165(60.89) |
Adverse event occurrence time - medication date (days) | |
N(missing) | |
Mean (SD) | 10.80(12.41) |
Median (Q1, Q3) | 6.50(2.00,15.00) |
Min, Max | 0.00,82.00 |
Body weight (Kg) | |
N(Missing) | 42(229) |
Mean (SD) | 77.88(27.27) |
Median (Q1, Q3) | 72.90(61.00,90.00) |
Min, Max | 32.40,170.00 |